At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

After several years in the doldrums, pharmaceutical companies and biotechs expect an uptick in dealmaking in 2025, with some ...

Unfortunately, there's already a lot of competition in the RSV vaccine space. Moderna's mRESVIA must contend with Abrysvo ...

New York Amsterdam News | Word In Black (WIB) - With the triad of respiratory viruses present in our day-to-day, it ...

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age ...

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

Morgan Stanley slashed its price target on Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) to $38 from $70 given the lowered revenue ...